Sarepta Therapeutics Inc’s recent filing unveils that its Director Nicaise Claude unloaded Company’s shares for reported $0.25 million on Mar 12 ’25. In the deal valued at $99.64 per share,2,491 shares were sold. As a result of this transaction, Nicaise Claude now holds 27,812 shares worth roughly $1.37 million.
Then, Nicaise Claude bought 2,491 shares, generating $248,226 in total proceeds.
Before that, Wigzell Hans Lennart Rudolf sold 10,500 shares. Sarepta Therapeutics Inc shares valued at $1,310,820 were divested by the Director at a price of $124.84 per share. As a result of the transaction, Wigzell Hans Lennart Rudolf now holds 22,840 shares, worth roughly $1.13 million.
H.C. Wainwright upgraded its Sarepta Therapeutics Inc [SRPT] rating to a Neutral from a a Sell in a research note published recently. A number of analysts have revised their coverage, including RBC Capital Mkts’s analysts, who decreased its forecast for the stock in late March from “an Outperform” to “a Sector perform”. Deutsche Bank began covering SRPT with “Hold” recommendation on February 11, 2025. Needham maintained its rating on November 27, 2024. It rated SRPT as “a Buy”.
Price Performance Review of SRPT
On Tuesday, Sarepta Therapeutics Inc [NASDAQ:SRPT] saw its stock fall -5.92% to $49.30. Over the last five days, the stock has lost -20.37%. Sarepta Therapeutics Inc shares have fallen nearly -59.45% since the year began. Nevertheless, the stocks have fallen -60.90% over the past one year. While a 52-week high of $173.25 was reached on 01/07/25, a 52-week low of $50.61 was recorded on 04/08/25. SMA at 50 days reached $94.49, while 200 days put it at $121.51.
Levels Of Support And Resistance For SRPT Stock
The 24-hour chart illustrates a support level at 47.04, which if violated will result in even more drops to 44.78. On the upside, there is a resistance level at 53.46. A further resistance level may holdings at 57.62. The Relative Strength Index (RSI) on the 14-day chart is 17.62, which indicates oversold technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -13.35, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 98.85%. Stochastics %K at 2.55% indicates the stock is a buying.
How much short interest is there in Sarepta Therapeutics Inc?
A steep rise in short interest was recorded in Sarepta Therapeutics Inc stocks on 2025-03-14, dropping by 65763.0 shares to a total of 4.85 million shares. Yahoo Finance data shows the prior-month short interest on 2025-02-14 was 4.92 million shares. There was a decline of -1.35%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on November 25, 2024 when H.C. Wainwright began covering the stock and recommended ‘”a Sell”‘ rating along with a $80 price target.
